Last reviewed · How we verify
NCT06607835
Cannabis Suppositories and Mindful Compassion Online Groups for Sexual Functioning
NA trial testing Mindful- compassion in Sexual Pain Disorders in 83 participants. Completed in 4 April 2024.
1 October 2023
Quick facts
| Lead sponsor | London Metropolitan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 83 |
| Start date | 2 July 2023 |
| Primary completion | 1 October 2023 |
| Estimated completion | 4 April 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Mindful- compassion
- Mindful-compassion and cannabis suppositories
Conditions studied
- Sexual Pain Disorders — all drugs for Sexual Pain Disorders →
Sponsor
London Metropolitan University
Who can join
18 and older, female only, with Sexual Pain Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Research aim: To determine how an online mindful-compassion intervention adjunct with cannabis suppositories might reduce vaginal pain during sexual intimacy among women post-gynaecological cancer treatment. Outcomes are also hoped to increase sexual functioning, well-being, sexual self-efficacy and quality of life. Research intention: If the combined mindful compassion and cannabis suppository intervention reduces vaginal pain and supports sexual and general well-being, then this research would be repeated on a larger scale targeting psychosexual services. A brief overview of the intervention: Mindfulness has been anecdotally discussed in reducing symptoms of vaginal pain and increasing overall well-being. A novel approach to pain management includes medical cannabis, which can be cannabidiol, tetrahydrocannabinol or both. Vaginal suppositories do not create a euphoric high in the same way as oral use, including inhalation. Quantitatively, randomisation will be based on whether participants use cannabis suppositories or not. This study does not randomise to cannabis groups owing to the legalities in the United Kingdom. Participants included eighty-three consenting participants. Of these, forty-one were using cannabis suppositories. The intervention was delivered for one month, and the follow-up was at twelve weeks. Qualitatively, participants were asked approximately eight open-ended feedback questions throughout the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Preliminary Investigation into the Use of Cannabis Suppositories and Online Mindful Compassion for Improving Sexual Function Among Women Following Gynaecological Cancer Treatment.
Banbury S, Tharmalingam H, Lusher J, Erridge S, et al · · 2024 · cited 1× · PMID 39768900 · DOI 10.3390/medicina60122020
Verify or expand the search:
- PubMed search for NCT06607835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other London Metropolitan University trials
Trials by the same sponsor.
- NCT07044284 — The Effects of Fractal Mindfulness Virtual Reality on Menopause Symptoms · NA · completed
- NCT06664346 — Cognitive Mindfulness Intervention Using Virtual Reality to Address Academic Procrastination and Academic Engagement · NA · completed
- NCT07296796 — The Impact of Mindful Compassion on Sexual Functioning and Quality of Life in Home Hospice Care · NA · completed
- NCT06435650 — The Use of Mindful Compassion and Cannabis Suppositories for Anal Pain Among Men Who Have Sex With Men · NA · completed
- NCT05167955 — Mindfulness-Based-Cognitive-Intervention for African Caribbean Men With Erectile Dysfunction · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06607835 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by London Metropolitan University
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06607835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing